Drug Database · Food supplement

RENAKULT

Lactobacillus acidophilus, Bifidobacterium longum, Streptococcus thermophilus, Bacillus coagulans

Food supplementKidney-marketedProbiotic2 registrations Kidney notes reviewed
Company: AMB HK ENTERPRISES INC; CORBRIDGE GROUP PHILS., INC Last updated: Audience: Licensed health professionals
Registered with the Philippine FDA as a FOOD SUPPLEMENT — no approved therapeutic claims. Not a substitute for prescribed treatment.

Kidney notes

Renakult is a probiotic with the same three organisms as Renadyl (Lactobacillus acidophilus, Bifidobacterium longum, Streptococcus thermophilus); one of its two Philippine registrations also lists Bacillus coagulans. Strain designations and colony counts are not given in the FDA record.

Evidence

  • No clinical trials of Renakult itself were identified on PubMed.
  • Its species overlap with Renadyl, whose small trials showed lower BUN in CKD stages 3 to 4 but no significant change in uremic toxins or quality of life on hemodialysis (Ranganathan 2009; Natarajan 2014). Probiotic effects are strain- and dose-specific, so these results cannot be transferred to Renakult.
  • Class evidence: probiotics alone did not lower indoxyl sulfate or p-cresyl sulfate in a meta-analysis of RCTs (Chen 2022), and biotic supplements did not lower serum creatinine in non-dialysis CKD (Liu 2023).

Cautions in kidney disease

  • Probiotic organisms can enter the bloodstream: whole-genome sequencing has linked Lactobacillus bacteremia in ICU patients to the probiotic capsule they were given. Avoid in critically ill patients, those with a central venous catheter (including a tunneled hemodialysis catheter), recent bowel surgery or gut barrier injury, and in kidney transplant recipients or others on immunosuppression unless the treating team agrees. [Yelin 2019]
  • Trial outcomes were blood urea nitrogen (BUN), creatinine, uremic-toxin levels and quality-of-life scores; no trial reports kidney failure, dialysis start, cardiovascular events or death.
  • Registered as a food supplement with no approved therapeutic claims: viable count, strain identity and storage stability are not verified by the FDA the way drug content is.
  • It does not replace evidence-based CKD care (blood pressure and glucose control, RAAS blockade, SGLT2 inhibitors where indicated, diet).

Bottom line

No product-specific evidence; class evidence is limited to surrogate markers. Same safety limits as any live probiotic, especially in transplant recipients and patients with a dialysis catheter.

Sources

  1. Ranganathan, N., Friedman, E. A., Tam, P., Rao, V., Ranganathan, P., & Dheer, R. (2009). Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: A 6-month pilot scale trial in Canada. Current Medical Research and Opinion, 25(8), 1919–1930. https://doi.org/10.1185/03007990903069249
  2. Natarajan, R., Pechenyak, B., Vyas, U., Ranganathan, P., Weinberg, A., Liang, P., Mallappallil, M. C., Norin, A. J., Friedman, E. A., & Saggi, S. J. (2014). Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. BioMed Research International, 2014, 568571. https://doi.org/10.1155/2014/568571
  3. Chen, L., Shi, J., Ma, X., Shi, D., & Qu, H. (2022). Effects of microbiota-driven therapy on circulating indoxyl sulfate and p-cresyl sulfate in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. Advances in Nutrition, 13(4), 1267–1278. https://doi.org/10.1093/advances/nmab149
  4. Liu, F., Liu, Y., Lv, X., & Lun, H. (2023). Effects of prebiotics, probiotics and synbiotics on serum creatinine in non-dialysis patients: A meta-analysis of randomized controlled trials. Renal Failure, 45(1), 2152693. https://doi.org/10.1080/0886022X.2022.2152693
  5. Yelin, I., Flett, K. B., Merakou, C., Mehrotra, P., Stam, J., Snesrud, E., Hinkle, M., Lesho, E., McGann, P., McAdam, A. J., Sandora, T. J., Kishony, R., & Priebe, G. P. (2019). Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nature Medicine, 25(11), 1728–1732. https://doi.org/10.1038/s41591-019-0626-9

Reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. renalcarematters.com, reviewed

FDA Philippines registrations

2 current food-supplement registrations under the brand RENAKULT. Registration status changes; confirm a product's current status on the FDA verification portal using its FR number.

Verify on PH FDA portal

LACTOBACILLUS ACIDOPHILUS, BIFIDOBACTERIUM LONGUM, STREPTOCOCCUS THERMOPHILUS & BACILLUS COAGULANS PROBIOTICS 600mg FOOD SUPPLEMENT CAPSULES

Ingredients
  • Lactobacillus acidophilus
  • Bifidobacterium longum
  • Streptococcus thermophilus
  • Bacillus coagulans
As registered: LACTOBACILLUS ACIDOPHILUS, BIFIDOBACTERIUM LONGUM, STREPTOCOCCUS THERMOPHILUS & BACILLUS COAGULANS PROBIOTICS 600mg
FR number
FR-2556753 · verify on the FDA portal
Registered as
Food supplement
Form
Capsule
Company
AMB HK ENTERPRISES INC
Issued
Not listed
Valid until
October 4, 2028
FDA risk class
High Risk
Application
Amendment

LACTOBACILLUS ACIDOPHILUS, BIFIDOBACTERIUM LONGUM & STREPTOCOCCUS THERMOPHILUS PROBIOTIC

Ingredients
  • Lactobacillus acidophilus
  • Bifidobacterium longum
  • Streptococcus thermophilus
As registered: LACTOBACILLUS ACIDOPHILUS, BIFIDOBACTERIUM LONGUM & STREPTOCOCCUS THERMOPHILUS PROBIOTIC
FR number
FR-4000009835092 · verify on the FDA portal
Registered as
Food supplement
Form
Other
Company
CORBRIDGE GROUP PHILS., INC
Issued
August 19, 2022
Valid until
August 19, 2027
FDA risk class
High Risk
Application
Initial
For health professionals. Data come from the FDA Philippines food-product registration database and may lag behind the official record. A food-supplement registration means the product may be sold as food; it is not an approval of safety or efficacy for any disease. Not a substitute for clinical judgment.